OIS: Ophthalmology Innovation & Investment – ReNeuron using hRPCs to treat inherited retinal degenerative diseases
Proactive Investors ‘ReNeuron focus on new clinical trials’
Proactive investors ‘Breakthrough to open up potential new revenue opportunities for Reneuron Plc’
Shares Investor Evening (Manchester) – October 2018
Proactive Investors : ‘All systems go’ with ReNeuron Group Plc looking to treat first PISCES III patient shortly
CFO fireside chat at ARM Cell & Gene Investor Day
Proactive Investors: Michael Hunt updates on product development
To view the full article click here.
Proactive Investors: ‘Lots to look forward to’ as ReNeuron gets go-ahead for phase IIb stroke trial
Michael Hunt, CFO of ReNeuron Group Plc (LON:RENE), tells Proactive they’ve been given the green light from US authorities to kick off a phase IIb study of its CTX cell therapy candidate for stroke disability.
Long-term data from the PISCES II trial earlier this year showed the treatment has the potential to improve the disability of stroke patients.
PISCES III – as this next study will be called – will be much bigger, recruiting 110 patients across 25 sites in the US.
The approval caps off a productive six months for the cell-based therapeutics specialist, during which it also started dosing patients in the phase II element of the ongoing phase I/II clinical trial of its hRPC stem cell therapy candidate for retinitis pigmentosa
Proactive Investors: Michael Hunt discusses very encouraging long-term stroke data
To view the full article click here…
Proactive Investors: ReNeuron gears up for Phase III stroke disability study
To view the full article click here…